Ashling Wahner

Articles

FDA Grants Fast Track Designation to ONCT-534 for Relapsed/Refractory mCRPC

October 27th 2023

The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.

Bezuclastinib Plus Sunitinib Shows Encouraging Safety and Efficacy Profile in R/R Second-Line GIST

October 25th 2023

The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.

Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population

October 23rd 2023

The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.

Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC

October 22nd 2023

Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.

Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer

October 20th 2023

Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Novel KRAS G12C Inhibitor Reflects Research Advances in NSCLC and CRC

October 19th 2023

David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.

HR+/HER2– Metastatic Breast Cancer Treatment Developments Continue to Unfold

October 19th 2023

Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.

Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm

October 19th 2023

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management

October 18th 2023

Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.

FDA Grants Fast Track Designation to DOC1021 for Glioblastoma

October 17th 2023

The FDA has granted a fast track designation to the dendritic cell vaccine DOC1021 for use as a potential therapeutic option in patients with glioblastoma multiforme.

The Arsenal of Metastatic Breast Cancer Imaging Modalities Continues to Expand

October 6th 2023

Rena D. Callahan, MD, discusses the current standards for breast cancer imaging modalities, the complexities of using bone biopsy, and the importance of continuing to study nonstandard imaging modalities to increase the accessibility of breast cancer imaging for metastatic disease.

Dostarlimab Plus Chemo Wins MHRA Approval for dMMR/MSI-H Primary Advanced/Recurrent Endometrial Cancer

October 6th 2023

The Medicines and Healthcare Products Regulatory Agency has authorized the use of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair-deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer.

Daily Adaptive Radiotherapy Delivers Improved Efficacy and Safety Outcomes in HNSCC

October 4th 2023

Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.

Multiple Myeloma Call-to-Action Plan Seeks to Ignite Widespread, Patient-Focused Change

October 3rd 2023

Faith E. Davies, MD, discusses the overarching goals of the Multiple Myeloma Call-to-Action, unmet needs that this plan seeks to alleviate, and ways in which all medical professionals could adopt these tenets into their practice to achieve global change in the care of patients with multiple myeloma.

FDA Grants Orphan Drug Designation to BDC-1001 in Gastric Cancers

October 2nd 2023

The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.

Systemic Review Sheds Light on Efficacy of Bispecific Antibodies in Extramedullary R/R Multiple Myeloma

September 28th 2023

Overall response rates with bispecific antibody monotherapy in patients with extramedullary relapsed/refractory multiple myeloma were lower than ORRs observed across all patients with relapsed/refractory multiple myeloma included in a systematic review evaluating the efficacy of this class of agents in this difficult-to-treat population.

Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML

September 27th 2023

Naval G. Daver, MD, discusses the rationale for investigating uproleselan combinations in patients with acute myeloid leukemia, the current role of quizartinib in patients with FLT3-ITD–mutated disease, and potential future directions with both these agents in the AML field.

Research Demonstrates the Importance of Effective Frontline Regimens for High-Risk Multiple Myeloma

September 27th 2023

Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.

Novel Sequencing Strategies May Expand Localized and Metastatic Breast Cancer Treatment Landscapes

September 27th 2023

Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.

Luspatercept Broadens Lower-Risk MDS Treatment Landscape

September 25th 2023

Guillermo Garcia-Manero, M, discusses key efficacy and safety findings from the COMMANDS trial; the significance of the FDA approval of luspatercept in patients with lower-risk MDS; and considerations for bringing this agent into clinical practice.